about
Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver diseaseRecommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National GuidelineManaging chronic hepatitis B: A qualitative study exploring the perspectives of people living with chronic hepatitis B in Australia.Dynamics of HCV RNA levels during acute hepatitis C virus infection.Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) studyPatterns of hepatitis C virus RNA levels during acute infection: the InC3 study.Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 studyHIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection.Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infectionHepatitis B-Related Concerns and Anxieties Among People With Chronic Hepatitis B in Australia.Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease BurdenDisease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infectionCase definitions for acute hepatitis C virus infection: a systematic review.Epidemiology and natural history of HCV infection.Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment.The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis.Hepatitis C treatment as prevention: evidence, feasibility, and challenges.Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study.Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection.Strategies to manage hepatitis C virus infection disease burden - volume 3.Hepatitis B knowledge and associated factors among people with chronic hepatitis B.Challenges in managing patients in Australia with chronic hepatitis B: the General Practitioners' perspective.Challenges to the effective delivery of health care to people with chronic hepatitis B in Australia.Distribution and risk factors of hepatitis B, hepatitis C, and HIV infection in a female population with "illegal social behaviour".Temporal variations of health indicators in Iran comparing with other Eastern Mediterranean Region countries in the last two decades.Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures.Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients.Trends and geographical inequalities of the main health indicators for rural Iran.Uptake of direct acting antiviral treatment for chronic hepatitis C in Australia.Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison.Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C.Sexual function: a comparison between male renal transplant recipients and hemodialysis patients.Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot SamplesCan we include genetic variants with high linkage disequilibrium into a multiple logistic model?
P50
Q24804864-FA6DCB4D-DB9E-48D8-8514-B132163EC3DDQ28076883-26D76143-4C7E-4FA8-BC81-61C4F6FAE593Q33836341-11FDB710-0190-4FE2-9E13-DBCD567E893CQ34771346-3EAED698-5CE1-4104-9754-FA704463C4DBQ34785317-89FEB310-8967-48E7-B691-68C8B8DAFF56Q35249648-396241DC-3F2C-4051-AD5A-5C2FE0493467Q35832850-3CDCF18B-D1E2-4F29-A8BC-FBCB474C5466Q36035679-D63EFE21-DAA4-4351-8ABC-054862F96915Q36134478-38D43F69-4407-457F-962D-DF7CEBF5BCB2Q36506119-8E61095F-B876-4ED9-8297-31FE84C4574BQ36611680-B843B443-0E90-4576-BE28-BB12B83DF984Q37231223-BF737E88-7918-42C9-9E50-9831415CE597Q37246465-21A5CA08-2FFA-4DAA-B669-5987223C7F84Q37569369-B3064766-82BB-4FAD-9E9C-7A15B3AF5A2CQ37678136-EB4747CA-4BC5-482D-AC23-FBFAF337C862Q38026416-4C74878A-B18A-474A-92BD-2BDAFBD49D4CQ38118578-ED9C1151-C1B4-4CE4-9044-15B4042127E3Q38838703-A12732C1-419F-4C14-801D-D8D3A0FCBB5AQ38948615-9B092B25-F69F-4CF0-AD6D-115392C418FAQ38948620-2705036E-96B9-4421-963A-B55048516B7AQ38993437-8448FCE6-4CBD-4BE3-8782-99F5DEE82A25Q39238761-509A83FD-F17E-44B8-860A-5A0D77D0695FQ39445534-98556465-9A68-4393-8D8F-C5E661F0893EQ40537260-2FBE7F3D-BE67-4B62-8BF0-A7FB6DDEC6E2Q40659995-B901A9A0-4101-410C-B6CA-1350DED364D5Q40932583-E06AA92E-B9EA-4166-A8A2-92685A8E7D14Q41653346-55034A13-0672-4969-A6C9-5D7A705A74CCQ42265055-F0CFFC87-1D13-4D1A-8DD3-F9436C73E033Q42643968-129207FA-EA00-4CB5-8548-2A04009AF3EAQ43024476-FA5C2726-D521-461E-99C1-7E5117617D22Q44893497-C0C9E0AA-95A2-496E-A441-F0F948EFFC72Q44988812-8677D93F-A61A-4569-B17A-644661E30FADQ45667974-98839FD2-373C-41AF-9579-86CA9E69F457Q46334302-7E440131-8CF0-42CF-A5C4-D16E8C21DB49Q47255195-D57E84EA-08BE-495C-ACC0-4E2F7E14EA21Q47384278-04B730EE-7C0D-41A5-9142-4A18889DA9CFQ50545974-82A6B1FE-BACA-4D8B-94C7-06B1AF2F093EQ51872944-F909A6F4-7A3B-48DB-BE14-B8ED1FF17E83Q58033017-BFA60A75-384B-4DCA-86F8-12E5768BD256Q58924218-3A682E25-7208-48BE-97FE-38A4979885F5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Behzad Hajarizadeh
@ast
Behzad Hajarizadeh
@en
Behzad Hajarizadeh
@es
Behzad Hajarizadeh
@nl
Behzad Hajarizadeh
@sl
type
label
Behzad Hajarizadeh
@ast
Behzad Hajarizadeh
@en
Behzad Hajarizadeh
@es
Behzad Hajarizadeh
@nl
Behzad Hajarizadeh
@sl
prefLabel
Behzad Hajarizadeh
@ast
Behzad Hajarizadeh
@en
Behzad Hajarizadeh
@es
Behzad Hajarizadeh
@nl
Behzad Hajarizadeh
@sl
P106
P1153
6506580362
P31
P496
0000-0003-2212-2028